Core Points - Huaxi Bio (688363.SH) announced that it received a notification from Huaxi Xinyu regarding share buybacks [1] - From August 27, 2025, to September 30, 2025, Huaxi Xinyu increased its holdings by 4,518,703 shares, accounting for 0.94% of the total share capital [1] - The total amount spent on the share buyback was RMB 257,478,738.40, exceeding the lower limit of the planned buyback amount of RMB 200 million [1] - The buyback plan has been completed [1]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][30]. Core Insights - The report highlights a significant decline in key consumer sub-sectors, with tourism attractions, hotel catering, and general retail experiencing drops of -11.65%, -8.38%, and -4.97% respectively during the week of September 22-26, 2025 [2][16]. - The Ministry of Commerce and other departments have issued guidelines to promote digital consumption, emphasizing support for instant retail, social e-commerce, and live-streaming e-commerce [3][23]. - TOPTOY, a subsidiary of Miniso, has submitted its IPO application to the Hong Kong Stock Exchange, with revenue growth from 679 million yuan in 2022 to 1.909 billion yuan in 2024, and a 58.5% year-on-year increase in the first half of 2025 [4][26]. Summary by Sections Market Performance - For the week of September 22-26, 2025, the retail trade, social services, and beauty care sectors fell by 4.32%, 5.92%, and 2.25% respectively, ranking 29th, 31st, and 25th among 31 primary industries [14][16]. Key Industry Data and News - The report notes a 5.6% year-on-year increase in daily flight volumes in the civil aviation sector, with domestic flights up 7.9% compared to 2019 [4][23]. - The report discusses the launch of the Tmall Double 11 pre-sale on October 15, 2025, and the support for cross-border shipping and return services on 12 overseas sites [4][27]. Key Company Announcements - Juzi Holding, the controlling shareholder of Juzi Biotechnology, has increased its stake to 54.45% through a purchase of approximately 105.6 million Hong Kong dollars worth of shares [4][28]. - Proya has launched a new ruby mask product, claiming to enhance skin firmness with a unique peptide formula [3][23]. Investment Recommendations - The report recommends focusing on companies such as Proya, Juzi Biotechnology, Marubi, Runben, and others within the beauty care and new consumption sectors [5][30].

证券代码：688363 证券简称：华熙生物 公告编号：2025-038 华熙生物科技股份有限公司 关于控股股东增持计划实施完毕暨增持股份结果 公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况 华熙生物科技股份有限公司（以下简称"公司"）的控股股东华熙昕宇投资 有限公司（以下简称"华熙昕宇"）基于对公司未来发展的信心和长期投资价值 认可，计划自 2025 年 8 月 8 日起的 6 个月内，使用自有资金或自筹资金，通过 上海证券交易所系统允许的方式（包括但不限于集中竞价、大宗交易等）增持公 司股份，增持金额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），增持 股份比例不超过公司总股本 1%，增持股票价格不超过 70 元/股。具体内容详见 公司于 2025 年 8 月 8 日在上海证券交易所网站（www.sse.com.cn）披露的《华 熙生物科技股份有限公司关于控股股东增持公司股份计划公告》（公告编号： 2025-028）。 增持计划的实施结果 公司于 2025 年 ...

致：华熙生物科技股份有限公司 北京市通商律师事务所(以下简称"本所")是经北京市司法局批准成立，依 法在中华人民共和国(以下简称"中国"，就且仅就本法律意见书而言，不包括 中国香港特别行政区、中国澳门特别行政区和中国台湾地区)从事法律业务的律 师事务所。本所作为华熙生物科技股份有限公司(以下简称"公司")的法律顾问， 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国 证券法》、中国证券监督管理委员会(以下简称"证监会")颁布的《上市公司收 购管理办法》(以下简称"《管理办法》")等有关法律、法规和规范性文件的规 定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，就公司控股股东 华熙昕宇投资有限公司(以下简称"华熙昕宇"或"控股股东"或"增持人")增 持公司股份(以下简称"本次增持")的相关事项出具本法律意见书。 本所及承办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则(试行)》等规定及本法律意见书出具日以 前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用 原则，进行了充分的核查验证，保证本法律意见所认定的事实真实 ...

Group 1 - The core point of the article is that Huaxi Bio announced a significant share buyback, with Huaxi Xinyu increasing its stake in the company by approximately 4.52 million shares, representing 0.94% of the total share capital, with a total investment of around RMB 257 million, exceeding the lower limit of the planned buyback amount of RMB 200 million [1] Group 2 - The share buyback took place between August 27, 2025, and September 30, 2025, through the Shanghai Stock Exchange trading system via centralized bidding [1] - The buyback plan has been completed successfully, indicating strong confidence from Huaxi Xinyu in Huaxi Bio's future performance [1]

证券代码：688363 证券简称：华熙生物 公告编号：2025-037 华熙生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 拟聘任会计师事务所的基本情况 （一） 机构信息 1. 基本信息 | 名称 | 致同会计师事务所（特殊普通合伙），前身是 1981 年成立的北 | | | | | --- | --- | --- | --- | --- | | | 京会计师事务所，2011 年经北京市财政局批准转制为特殊普 | | | | | | 通合伙，2012 年更名为致同会计师事务所(特殊普通合伙) | | | | | 成立日期 1981 | 年 特殊普通合伙企业 | 组织形式 | | | | 注册地址 | 北京市朝阳区建国门外大街 | 22 | 号赛特广场 | 5 层 | | 首席合伙人 李惠琦 | 239 人 | 上年度末合 | | | | | | 伙人数量 | | | | 上年末执业人员 | 注册会计师人数 | 1359 人 | | | | 数量 | 签署过证券服务业 | 445 ...

Core Viewpoint - The controlling shareholder of Huaxi Biological, Huaxi Xinyu Investment Co., Ltd., has completed a share buyback plan, increasing its stake in the company significantly [1] Summary by Relevant Sections - **Share Buyback Details** - From August 27, 2025, to September 30, 2025, Huaxi Xinyu Investment Co., Ltd. acquired a total of 4.5187 million shares through centralized bidding on the Shanghai Stock Exchange, representing 0.94% of the company's total share capital [1] - The total amount spent on the buyback was 257 million yuan [1] - **Shareholding Changes** - Prior to the buyback, Huaxi Xinyu held 283 million shares, accounting for 58.86% of the total shares [1] - After the buyback, the total shares held increased to 290 million, raising the ownership percentage to 60.11% [1] - **Completion of Buyback Plan** - The share buyback plan has been fully implemented as of the announcement date [1]

Core Insights - The medical beauty sector experienced a slight increase of 0.15% on September 30, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Sector Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu (000615) closed at 3.34, up 1.83% with a trading volume of 122,900 shares and a turnover of 41.15 million yuan [1] - Huaxi Biological (688363) closed at 55.42, up 0.73% with a trading volume of 29,800 shares and a turnover of 164 million yuan [1] - Aimeike (300896) closed at 181.55, down 0.36% with a trading volume of 24,000 shares and a turnover of 43.5 million yuan [1] - Jinbo Biological (832982) closed at 281.59, down 0.95% with a trading volume of 5,375 shares and a turnover of 152 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 23.11 million yuan from institutional investors, while retail investors contributed a net inflow of 31.04 million yuan [1] - Detailed capital flow for key stocks indicates: - Huaxi Biological experienced a net outflow of 9.59 million yuan, down 5.83% [2] - *ST Meigu had a net outflow of 1.25 million yuan, down 3.03% [2] - Aimeike faced a significant net outflow of 34.29 million yuan, down 7.89% [2]

9月29日，由CCTV-1《大国品牌养成记》("简称《大国品牌》")联合全球知名增长战略咨询公司沙利文· 头豹研究院和中国人民大学新闻学院共同主办的"2025令人尊敬的品牌发布仪式"，在北京新华书店总店 举行。 当前，全球政经格局发生深刻变革，中国经济亦进入以高质量发展为代表的新阶段。品牌建设已成为推 动中国制造向中国创造转变、中国速度向中国质量转变、中国产品向中国品牌转变的关键力量。 本次活动即围绕新时代中国企业品牌化发展，以"声誉力与长期价值共生"为主题，现场发布了"2025年 中国令人尊敬的品牌"无形资产及声誉活跃30强榜单。中国石化、中国中车、三一集团、宝武钢铁、保 利集团、南方电网、双良集团、海澜集团、娃哈哈、纳爱斯集团、华熙生物等知名品牌入选。 据主办方介绍，本次评选基于严谨的评估模型，从市场与财务表现、品牌影响与声誉资产、创新与全球 竞争力、社会责任与可持续四大维度，对参选品牌进行了系统性评估。首批入选的30家中国企业来自高 端制造、能源交通、人工智能、生物科技、日用消费等多个领域。它们不仅在经济指标上表现突出，更 在技术原创、绿色发展、雇主品牌、国际影响力等方面树立了行业标杆。其发展实践充分证 ...

Group 1 - The core viewpoint of the article is the strategic collaboration between Huaxi Bio (688363.SH) and Beijing Sails Pharmaceutical Technology Co., Ltd. in various fields including new veterinary drugs, innovative medical devices, and pet health [1] - The partnership aims to launch multiple clinically needed and high-tech innovative products over the coming years [1] - This collaboration is expected to contribute to the rapid development of the pet medical industry [1]